多发性骨髓瘤肾损害早期评估的研究进展

[1]	DIMOPOULOS M A,KASTRITIS E,ROSINOL L,et al.Pathogenesis and treatment of renal failure in multiple myeloma[J].Leukemia,2008,22:1485-1493.
[2]	KYLE R A,GERTZ M A,WITZIG T E,et al.Review of 1027 patients with newly diagnosed multiple myeloma[J].Mayo Clin Proc,2003,78:21-33.
[3]	TERPOS E,KATODRITOU E,TSIFTSAKIS E,et al.Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration[J].Haematologica,2009,94:372-379.
[4]	ABBOTT K C,AGODOA L Y.Multiple myeloma and light chain-associated nephropathy at end-stage renal disease in the United States:Patient characteristics and survival[J].Clin Nephrol,2001,56:207-210.
[5]	ELEUTHERAKIS-PAPAIAKOVOU V,BAMIAS A,GIKA D,et al.Renal failure in multiple myeloma:Incidence,correlations,and prognostic significance[J].Leuk Lymphoma,2007,48:337-341.
[6]	邹剑峰,侯健.多发性骨髓瘤的肾损害的发病机制及防治进展[J].国际输血及血液学杂志,2007,30(4):323-327.
[7]	BLADE J,ROSINOL L.Renal,hematologic and infectious complications in multiple myeloma[J].Best Pract Res Clin Haematol,2005,18:635-652.
[8]	MONTSENY J J,KLEINKNECHT D,MEYRIER A,et al.Long-term outcome according to renal histological lesions in 118 patients with monoclonal gammopathies[J].Nephml Dial Transplant,1998,13:1438-1445.
[9]	DIMOPOULOS A, TERPOS E,CHANNA-KHAN A,et al.Renal impairment in patients with multiple myeloma:a consensus statement on behalf of the International Myeloma Working Group[J].J Clin Oncol,2010,28:4976-4984.
[10]	GRUBB A,BJÖRK,NYMAN U,et al.Cystatin C,a marker for successful aging and glomerular filtration rate,is not influenced by inflammation.[J].Scand J Clin Lab Invest,2011,71:145-149.
[11]	DHARNIDHARKA V R,KWON C,STEVENS G.Serum cystatin C is superior to serum creatinine as a marker of kidney function:a meta-analysis[J].Am J Kidney Dis,2002,40:221-226.
[12]	CONTI M,MOUTEREAU S,ZATER M,et al.Urinary cystatin C as a specific marker of tubular dysfunction[J].Clin Chem Lab Med,2006,44:288-291.
[13]	CONTI M,MOUTEREAU S,ESMILAIRE L,et al.Should kidney tubular markers be adjusted for urine creatinine? The example of urinary cystatin C[J].Clin Chem Lab Med,2009,47:1553-1556.
[14]	DEVARAJML P.Emerging biomarkers of acutekidney injury[J].Contrib Nephrol,2007,56:203-212.
[15]	BOLIGNANO D,DONATO V,COPPOLINO G,et al.Neutrophil gelatinase-associated lipoealin(NGAL)as a marker of kidney damage[J].Am J Kidney Dis,2008,52:595-605.
[16]	TULADHAR S M,PUNTMANN V O,SONI M,et al.Rapid detection of acute kidney injury by plasma and urinary neutrophil gelatinase-associated lipocalin after eardiopulmonary bypass[J].J Cardiovase Pharmacol,2009,53:261-266.
[17]	HAASE-FIELITZ A,BELLOMO R,DEVARAJAN P,et al.Novel and conventional serum biomarkers predicting acute kidney injury in adult cardiac surgery--a prospective cohort study[J].Crit Care Med,2009,37:553-560.
[18]	HAASE M,BELLOMO R,DEVARAJAN P,et al.Novel biomarkers early predict the severity of acute kidney injury after cardiac surgery in adult[J].Ann Thorac Surg,2009,88:124-130.
[19]	FU K Y,CHEN R U,CAI J H,et al.Significance of detection of urinary sediment,RBP,NAG and renal pathological biopsy in analysis of acute renal failure[J].China Tropical Medicine,2009,9:1106-1107.
[20]	HUTCHISON C A,BRIDOUX F.Renal impairment in multiple myeloma:time is of the essence[J].J Clin Oncol,2011,29:312-313.
[21]	WIRK B.Renal failure in multiple myeloma:a medical emergency[J].Bone Marrow Transplant.2011,46:771-783.